SunGran is the key product of Shanghai Sunway Biotech Company Ltd. As an injection medicine launched in the domestic market this year, SunGran has achieved satisfactory sales in the past few months. It is widely used in major hospitals in Shanghai and gradually replaces the imported products of the same kind.

SunGran was developed by the PLA Medical Science Institute. The product is a recombinant granulocyte-colony stimulating factor, an innovative product of genetic engineering manufactured by Sunway Biotech using the recombinant DNA technology. The rhG-CSF has the same bio-activity as that of the natural counterpart. This pharmaceutical product represents the achievement of the Biotechnology Project of the "863" National Advanced Technology Research and Development Program.

G-CSF is one of the major cell factors that regulate blood formation in marrow. It selectively acts on and enhances the proliferation and differentiation of granular hemopoietic stem cells, and activates the functions of these stem cells. SunGran can induce the hemopoietic stem cells in marrow to enhance their division, proliferation and maturation. It causes the release of mature neutrophils into the peripheral blood steam and increase the number of neutrophils in the body.

SunGran is suitable for the treatment of neutropenia caused by cancer chemotherapy. After using marrow-suppressing chemotherapy medicines, injection of this project helps cancer patients prevent a decrease in neutrophils. It also helps shorten the granulocyte shortage period and accelerates the recovery of neutrophils, thus reducing the risk of suffering from secondary infection. It is considered a valuable adjunct medicine for heavily dosed chemotherapy.